Leger Clinic, a leading provider of testosterone replacement therapy (TRT), has officially joined the Medichecks Group, marking a major step forward in making high-quality TRT more accessible and affordable for men across the UK.
The acquisition aligns with Medichecks’ vision for being part of everyone’s journey to better health — helping men overcome barriers to diagnosis and treatment for testosterone deficiency.
Breaking down barriers to treatment
Testosterone deficiency remains an under-recognised condition, often dismissed as a natural part of ageing. Yet, symptoms such as fatigue, low mood, brain fog, and reduced sex drive can significantly impact quality of life. Despite the growing need, many men struggle to access treatment due to a lack of recognition and limited NHS options. Leger has been at the forefront of testosterone therapy for over 25 years, and now, as part of the Medichecks Group, it will streamline access to testing, treatment, and expert-led care.
Seamless monitoring and treatment
Blood testing plays a vital role in TRT, ensuring patients receive safe and effective treatment. With Medichecks’ advanced blood testing services now fully integrated into Leger’s care model, patients will no longer need to source external tests. This means faster results, simpler processes, and lower costs — delivering a seamless experience from initial diagnosis to ongoing treatment.
Dr Douglas Savage, Medical Director at Leger, commented:“Testosterone deficiency is a real issue. Patients tell us they’ve lost their get-up-and-go, they’re miserable, and their partners are noticing it too. I’ve seen firsthand how TRT can transform men’s lives. It’s not just about increasing testosterone — it’s about giving men back their energy, confidence, and drive. By joining Medichecks, we can make monitoring simpler, more affordable, and ensure men get the care they need without unnecessary barriers.”
Addressing a hidden men’s health crisis
Testosterone levels in men have been steadily declining by approximately 1% per year due to environmental, lifestyle, and medical factors. Despite this, awareness and access to treatment remain low. Recent Medichecks data shows that more than one in five men tested in 2024 had low or borderline testosterone levels, yet many struggle to get the support they need.
Helen Marsden, co-founder of Medichecks, highlighted the impact of this collaboration:“At Medichecks, we’re committed to making healthcare simple and accessible. Acquiring Leger means we’re ensuring that more men can benefit from expert TRT treatment backed by seamless, high-quality monitoring. We want men to take control of their health and feel their best again.”
Leger’s core mission remains the same: to provide good value, expert-led testosterone therapy with clear, transparent pricing. By cutting out unnecessary complexity, its integration into Medichecks ensures patients get the care they need quickly, safely, and cost-effectively.
Find out more here: https://healthchecks.medichecks.io/
